Juvaris BioTherapeutics
Burlingame, California, United States
About Juvaris BioTherapeutics
Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $63.1M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Oct 2010)
- Website: juvaris.com
- Phone: 925-399-6200
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/juvaris-biotherapeutics-2558036 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.